12 October2026: DR30206 fusion protein received China IND approval for combination therapy in HNSCC
Huadong Medicine’s DR30206, an antibody fusion protein has received China NMPA approval to initiate a clinical trial in combination with standard chemotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma
The approval enables clinical evaluation of the combination in HNSCC, building on DR30206’s ongoing phase 1/2 development across advanced solid tumors. Earlier studies have reported a favorable safety profile and preliminary antitumor activity signals
The program addresses the need for additional treatment options in recurrent or metastatic HNSCC, where disease progression and resistance to available therapies remain significant challenges
DR30206 is a triple-targeting antibody fusion protein that simultaneously targets PD-L1, VEGF and TGF-β. It is designed to restore antitumor immune activity through PD-1/PD-L1 pathway blockade, inhibit tumor angiogenesis through VEGF neutralization, and reduce immunosuppression by targeting TGF-β
Strategically, the new IND approval broadens DR30206’s clinical development across multiple solid tumors and combination regimens. Its triple-targeting mechanism differentiates the program from conventional checkpoint inhibitors and supports Huadong Medicine’s strategy of developing multi-targeted biologics for oncology